A clinical-stage biotech firm which is devoted to the development of targeted treatments for cancer & diabetes using its signature live-cell encapsulation technology known as cell-in-a-box, PharmaCyte Biotech, Inc., made an announcement today that has tapped into a new research agreement with the Australia’s University of Technology Sydney to develop a new version of Melligen cells for the treatment of diabetes with the possibility to express higher levels of insulin.
The Chief Executive Officer at PharmaCyte’s, Kenneth L. Waggoner, stated that We are delighted to have come to an agreement with University of Technology Sydney that enables us to take the Melligen cells to the next level in our development of a ‘bioartificial pancreas’ for the treatment of Type I & insulin-dependent Type II diabetes. If we get successful, it will bring to completion several years of research which have been conducted by Professor Ann Simpson & her colleagues at the University of Technology Sydney, as well as, PharmaCyte in creating these outstanding insulin-producing cells.
In response to the levels of blood sugar in the body, Melligen cells are genetically engineered to produce, store, as well as, release insulin. PharmaCyte has obtained the exclusive all over the world license rights from the University of Technology Sydney to utilize these cells for developing a therapy for Type I and insulin-dependent Type II diabetes. Using the Cell-in-a-Box tech, PharmaCyte plans to shelter Melligen cells from immune system attack in the body and hence function as a bioartificial pancreas for purposes of insulin production.
The work undertaken by University of Technology Sydney, PharmaCyte, and PharmaCyte’s International Diabetes Consortium over the past 2 years has given birth to an opportunity for re-engineering the Melligen cells to increase their insulin production, as well as, the bioactivity of the produced insulin.